TARGETED MPN MOLECULAR RESEARCH
Accutest LyoMorph-Q
MPN Mutation Panel Kit
Cost-effective and highly sensitive qPCR / 1-step RT-qPCR kit including lyophilized inhibitor-tolerant reagent mix with multiplex target-specific primer-probe mixes for detection of BCR::ABL fusions and variants in JAK2, CALR and MPL for blood-cancer research.
*Nominal capacity before controls, repeats or invalid reactions. Three reactions are required for complete panel coverage.
3 multiplex reactions
fusion targets
across panel targets
reported 95% LoD
complete panel coverage
One LyoMorph-Q platform. A growing oncology portfolio.
LyoMorph-Q uses a lyophilized inhibitor-tolerant reagent mix with universal mastermix chemistry across targeted mutation panels. Compatible assays that share a cycling profile can be planned together on a 96-well qPCR plate; RNA and DNA profiles for the MPN panel are run separately.
Focused multi-analyte coverage
Combine BCR::ABL fusion targets with JAK2, CALR and MPL variants in a defined panel.
Growing assay menu
Build a scalable targeted-testing menu across established solid- and blood-cancer research panels.
Custom assay development
Discuss bespoke targets and panel combinations, including feasibility and low-minimum-order options.
Oncology technical support
Jant and shard-dx™ can support instrument compatibility, assay selection, evaluation planning and technical review.
Accutest LyoMorph-Q oncology assays are powered by SHARD DIAGNOSTICS™ (Nottingham, England). All products are for Research Use Only and are not for use in diagnostic procedures.
Multi-analyte MPN research in three reactions
The panel combines simplified 1-step RT-qPCR for RNA fusion targets with qPCR for DNA mutation targets, including SNVs, SNPs and indels.
Universal mastermix chemistry, fixed thresholding and quantified controls support practical integration into focused oncology-research workflows.
Use familiar qPCR workflows
Simple to adopt by using your existing cycler and expertise.
Support broad input requirements
Supports inputs from 1–100 ng, with enhanced detection enabled by higher input where appropriate.
Simplify analysis
Fixed thresholding supports simplified analysis through enhanced specificity.
Reduce cold-chain burden
Ambient shipping and lyophilized reagents support practical distribution and laboratory adoption.
Defined MPN-associated targets across three multiplex reactions
The panel covers 10 mutation and fusion targets using RNA and gDNA, with an ABL A1A2 internal control and RNase P internal control included in the appropriate reactions.
Low-copy detection across focused MPN targets
Reported performance is target dependent. Across the MPN panel, reported 95% VAF limits of detection range from 0.01% to 0.03%, corresponding to approximately 3–10 mutant copies.
Specificity in the reported study conditions
Specificity was reported using wild-type material at the stated study input.
Results describe the reported study conditions and do not guarantee that false positives are impossible in every sample or laboratory.
| Reaction | Target | Variant / fusion | Sample | Reported 95% VAF LoD | Mutant copies at LoD |
|---|---|---|---|---|---|
| 1 | BCR::ABL | E13A2 | RNA | 0.01% | 3 |
| 1 | BCR::ABL | E14A2 | RNA | 0.01% | 3 |
| 1 | BCR::ABL | E1A2 | RNA | 0.01% | 3 |
| 1 | ABL | A1A2 internal control | RNA | Not applicable | Not applicable |
| 2 | JAK2 | V617F | gDNA | 0.01% | 3 |
| 2 | MPL | W515L | gDNA | 0.016% | 5 |
| 2 | MPL | W515K | gDNA | 0.01% | 3 |
| 2 | MPL | W515A | gDNA | 0.01% | 3 |
| 2 | RNase P | Internal control | gDNA | Not applicable | Not applicable |
| 3 | CALR | L367fs*46 | gDNA | 0.01% | 3 |
| 3 | CALR | K385fs*47 | gDNA | 0.01% | 3 |
| 3 | MPL | S505N [SNP] | gDNA | 0.03% | 10 |
Three reactions for integrated RNA and DNA research
Extract and quantify
Prepare RNA and gDNA and verify input concentration.
Reconstitute reagents
Rehydrate the lyophilized reagents according to the current protocol.
Prepare three reactions
Set up the BCR::ABL, JAK2/MPL and CALR/MPL reactions with appropriate controls.
Run and interpret
Use the specified RNA or DNA cycling profile and fixed-threshold analysis settings.
MPN panel FAQs
Which targets are included?
The three reactions cover BCR::ABL E13A2, E14A2 and E1A2; JAK2 V617F; MPL W515L, W515K, W515A and S505N; and CALR L367fs*46 and K385fs*47. ABL A1A2 and RNase P provide reaction-specific internal-control signals.
Does the panel use RNA, DNA or both?
Both. Reaction 1 uses RNA for BCR::ABL fusion detection. Reactions 2 and 3 use genomic DNA for JAK2, MPL and CALR targets.
Do RNA and DNA reactions use the same cycling profile?
No. The kit uses a universal inhibitor-tolerant reagent mix, but its RNA and DNA reactions use separate cycling profiles. Run each reaction set using the applicable cycling conditions in the current protocol.
Is the assay quantitative?
No. The panel is a qualitative mutation and fusion detection assay. The reported VAF and mutant-copy values describe analytical sensitivity under the stated study conditions; they do not make the assay quantitative.
Which instrument is verified?
The supplied performance data were generated across multiple real-time PCR instruments. Contact Jant for current instrument-specific compatibility information and technical support from Jant and shard-dx™.
How is the kit shipped?
The lyophilized kit supports ambient shipping. Follow the current product documentation for component-specific storage, reconstitution and stability requirements after receipt.
Is this MPN workflow a fit for your laboratory?
Tell us your sample types, target requirements and qPCR instrument. Jant’s molecular team can help review compatibility, documentation and evaluation needs.


